INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy
NCT: NCT07727395 · NOT_YET_RECRUITING
Brief Summary
The NEWLINE trial is a multicenter, randomized, open-label, blinded endpoint (PROBE) trial evaluating whether adjunctive low-dose intra-arterial alteplase administered immediately after successful endovascular thrombectomy improves functional outcomes in adults with acute ischemic stroke due to anterior circulation large vessel occlusion. Eligible participants achieving successful reperfusion (eTICI 2b-3) within 24 hours of symptom onset will be randomized 1:1 to receive intra-arterial alteplase plus standard care or standard care alone. The primary outcome is functional independence (modified Rankin Scale score 0-1) at 90 days.
Frequently Asked Questions
What is INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy?
INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy is a clinical trial registered under NCT07727395. Current status: NOT_YET_RECRUITING.
What is the status of NCT07727395?
The current status of NCT07727395 (INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy) is: NOT_YET_RECRUITING.
When did INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy start?
INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy started on 2026-08-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.